Empirico

Executive Summary

Empirico is a clinical-stage biotechnology company integrating human genetics-driven target discovery with siRNA drug development. Its platform identifies and validates genetic variants that protect against common diseases, then designs siRNA therapies that mimic these protective effects. By leveraging large-scale genetic data and proprietary computational tools, Empirico aims to develop first-in-class or best-in-class medicines with high translational probability. The company's lead program, targeting APOC3 for cardiovascular disease, has advanced into Phase 1 clinical trials, reflecting the platform's potential to rapidly convert genetic insights into therapeutic candidates. Empirico's approach stands out for its focus on mimicking naturally occurring protective mutations, which may reduce development risk and improve efficacy. With a strong intellectual property position and a seasoned management team, the company is well-positioned to capitalize on the growing convergence of genomics and RNA therapeutics.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 APOC3 siRNA program interim data readout60% success
• Q1 2027IND filing for second program targeting ANGPTL3 or PCSK970% success
• H2 2026Partnership or licensing deal with a larger pharmaceutical company50% success